by Combat Cancer | Aug 30, 2025 | News
Bladder cancer is the 9th most common cancer worldwide, the 5th most common in Europe, the 6th most common in the US and the 11th most common in the UK. Around 70-75% of cases are NMIBC, where the tumour is confined to the tissues lining the bladder wall. In high-risk...
by Combat Cancer | Aug 23, 2025 | News
Check out this short video showing how to safely and easily mix 80mg of mitomycin C into 40ml of fluid and administer it via the Combat BRS (Bladder Recirculation) HIVEC® kit for treating non-muscle-invasive bladder cancer: This is the dose being used in the...
by Combat Cancer | Aug 16, 2025 | News
Non–muscle–invasive bladder cancer (NMIBC) presents a significant therapeutic challenge. Nearly 70% of NMIBC cases recur, and a considerable subset progress to muscle invasion, requiring radical cystectomy – a procedure which many patients either refuse or...
by Combat Cancer | Aug 9, 2025 | News
Intravesical Bacillus Calmette‑Guérin (BCG) following transurethral resection of bladder tumour (TURBT) remains the primary treatment strategy for intermediate‑ and high‑risk non‑muscle‑invasive bladder cancer (NMIBC). Nevertheless, around four in ten patients...
by Combat Cancer | Aug 1, 2025 | News
In pancreatic ductal adenocarcinoma (PDAC), the most common and deadliest form of pancreatic cancer, pancreatic cancer cells drastically reprogram nearby normal fibroblasts – cells that normally maintain tissue structure and repair – to become...
Recent Comments